Selventa, Rosa Combine Efforts to Provide In Silico Preclinical Assessments for Drug Development

Selventa and Rosa plan to combine knowledge assets, proprietary data, physiologic model libraries, and expertise in several disease areas with the aim of helping clients make better drug discovery and development decisions.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories